Longevity Research Roundup: Interventions & Biomarkers (August 2026)

This week's roundup features a PAI-1 inhibitor reversing biological age, optimal resistance training doses, new NAD+ insights, and psilocybin for neuroplasticity.

# Longevity Research Roundup: Interventions & Biomarkers (August 2026)

The pursuit of extended healthspan and improved longevity continues at a relentless pace, with fresh insights emerging almost daily. This week, we're dissecting several pivotal developments – from clinical trials testing combined lifestyle interventions to promising small-molecule geroprotectors and eye-opening insights into the very nature of biological ageing. What's particularly exciting is the shift towards human-centric data, offering more tangible takeaways for those of us keen to apply these findings. So, let’s get stuck in.

FAXAge Trial: Fasting and Exercise – A Combined Strategy for Ageing?

**What was found:** Researchers have just published the study protocol for "FAXAge", a randomised, controlled clinical trial. This ambitious trial aims to assess the combined impact of structured fasting and exercise on biological age and various ageing pathways. While full results are still a way off, the protocol details a rigorous approach comparing a fasting-plus-exercise group against a control, utilising a suite of markers including DNA methylation clocks and inflammatory profiles to gauge effectiveness [5].

**Why it matters:** This isn't just another study; it represents a significant methodological leap. Instead of isolating variables like fasting *or* exercise, FAXAge investigates the synergistic effects of stacking these well-established longevity levers. If successful, it could provide a practical, evidence-based blueprint for integrating time-restricted eating, periodic fasting, and targeted exercise into a cohesive healthspan programme, moving beyond drug-centric approaches. Our editorial take is that these kinds of multi-modal, integrated lifestyle interventions are often overlooked in favour of a 'magic pill' narrative, but they represent the true foundation of sustainable longevity. It also offers a potential answer to a crucial question: *what precise combination of these interventions moves validated ageing clocks?*

**Actionable Takeaway:** Keep an eye on the FAXAge trial's eventual results. In the meantime, consistently combining structured exercise with some form of time-restricted eating or periodic fasting is a low-risk, high-potential strategy for improving metabolic health and potentially slowing biological ageing. Consider experimenting with a 14-16 hour daily fasting window a few days a week, alongside your regular training regimen.

PAI-1 Inhibitor TM5614: Biological Age Reversal in Months

**What was found:** A clinical trial involving 20 older adults tested TM5614, a plasminogen activator inhibitor-1 (PAI-1) inhibitor, over a four-month period. Participants experienced an average biological age reversal of approximately 2-3 years, based on composite health and ageing metrics. While one summary mentioned a headline figure of "23 years younger", it was quickly clarified that the actual mean effect was a more modest, yet still significant, 2-3 years [5].

**Why it matters:** PAI-1 plays a critical role in inflammaging, fibrosis, and vascular ageing, with high levels linked to senescent cell accumulation. A small-molecule geroprotector that can measurably shift biological age metrics in humans within a few months is a huge deal. It puts TM5614 in the same conceptual league as early senolytics, targeting fundamental mechanisms of ageing. If this finding can be replicated in larger, more diverse cohorts and linked to hard clinical outcomes like reduced frailty, cardiovascular events, or dementia, TM5614 (or similar PAI-1 modulators) could be a groundbreaking addition to our longevity toolkit, focusing on vascular and metabolic resilience. For more on how drugs like this relate to `/peptides`, which often modulate similar pathways, you might find our recent articles insightful. It's an exciting development in pharmacological geroprotection. Please remember, like all novel compounds discussed on Longevity Stack, this is a research-stage drug and any personal consideration should involve thorough due diligence and professional medical advice [/legal/disclaimer].

**Actionable Takeaway:** While TM5614 isn't publicly available, understanding PAI-1's role highlights the importance of managing inflammation and vascular health. Lifestyle interventions such as regular exercise and a balanced diet can help keep PAI-1 levels in check. Continue to prioritise cardiovascular health through diet, exercise, and stress management, as these indirectly support the pathways PAI-1 influences.

Long-Term Strength Training: Over 147,000 Adults and 30 Years of Data

**What was found:** A monumental 30-year longitudinal study, analysing data from over 147,000 adults, investigated the relationship between weekly resistance training volume and mortality. The sweet spot? Approximately 90-119 minutes per week, which was associated with a significant reduction in both all-cause mortality and, notably, death from neurological diseases [6].

**Why it matters:** We’ve long championed strength training, but this study provides exceptionally robust, long-term evidence for its dose-response impact on actual mortality endpoints, not just proxies like VO₂max. The finding regarding reduced neurological mortality is particularly compelling, suggesting resistance training's benefits extend beyond mere muscle preservation to potentially influence brain ageing, perhaps via glucose utilisation, myokines, or neurotrophic factors. This reinforces that `/protocols/muscle-preservation-50-plus` is not just about physical capacity but also about maintaining cognitive resilience. For anyone designing a longevity protocol after 50, ~90-120 minutes of well-structured strength work per week should be non-negotiable, complementing cardiovascular training.

**Actionable Takeaway:** Aim for 2-3 resistance training sessions per week, totalling roughly 90-120 minutes. Focus on compound movements targeting major muscle groups, ensuring progressive overload. If you're new to it, start with bodyweight or light weights and gradually increase intensity. This isn't just about looking good; it's a profound investment in your future health and cognitive function.

Piceatannol: A Senolytic-Like Analogue for Multi-Organ Ageing

**What was found:** In aged mice, piceatannol – a plant-derived stilbenoid similar to resveratrol – demonstrated impressive senolytic-like and anti-inflammatory properties. It improved motor coordination and spatial memory, reduced senescent cell burden in the heart and kidney, and lowered systemic inflammatory proteins. A small human trial for cosmetic purposes (10mg/day) also suggested good safety and improved skin hydration [7].

**Why it matters:** This positions piceatannol as a promising nutraceutical-class compound with potential senomodulatory effects. Its dual action on senescent cells and inflammation in key ageing organs like the heart and kidney is significant. This could make it a gentler, titratable addition to a geroprotective stack, potentially sitting alongside other compounds like `/supplements/spermidine` or `/supplements/urolithin-a`. The existing, albeit limited, human safety data from cosmetic trials provides a crucial initial signal before larger-scale ageing trials. This area of `/supplements` research is rapidly expanding.

**Actionable Takeaway:** While human data for longevity benefits are nascent, piceatannol looks like a promising contender. If you’re already using supplements, consider exploring this compound as a potential addition to your anti-inflammatory and senolytic support stack, keeping in mind the current stage of research. Consult a healthcare professional before adding new supplements, especially if you have underlying health conditions.

ATM Kinase: The Molecular Switch to Cellular Senescence

**What was found:** New mechanistic research highlights ATM kinase, an enzyme known for its role in DNA damage response, as a critical molecular switch determining whether cells continue to divide or enter a senescent state. The study pinpoints upstream signalling events that activate ATM in response to age-related stress and damage, positioning it as a gatekeeper of long-term tissue regenerative capacity [2].

**Why it matters:** This discovery provides a highly targetable node in the complex cascade from chronic stress and DNA damage to irreversible senescence. Modulating ATM activity could offer new avenues for senolytic or senomorphic drug design, potentially preserving stem cell pools and delaying the exhaustion of proliferative capacity. For the world of AI-driven drug discovery, ATM-centred networks become a high-value mechanistic substrate for developing novel longevity interventions. This foundational research deepens our understanding of the `/research` landscape in ageing.

**Actionable Takeaway:** This is fundamental research, not immediately actionable for individuals. However, it underscores the importance of minimising cellular stress and DNA damage through antioxidant-rich diets, reduced exposure to environmental toxins, and robust sleep. These general health practices indirectly support cellular repair mechanisms that prevent ATM from being over-activated into a senescence-inducing state.

Multi-Organ Ageing Map: NAD-Related Pathways as Intervention-Responsive

**What was found:** Scientists have created a comprehensive cross-organ ageing atlas, examining how various molecular pathways change with age across 17 organs and their responsiveness to interventions. This analysis specifically identified the NAD-related metabolic pathway as one of the few circuits that appear genuinely modifiable by intervention across multiple organs [2].

**Why it matters:** This offers a systems-level view that helps refine our understanding of NAD biology. It suggests that while NAD decline isn't universally uniform across all tissues with age, certain NAD-related pathways are indeed responsive to interventions. This supports a more targeted approach to NAD+ strategies, focusing interventions like NR or `/supplements/nmn` where the biology shows clear modifiability, rather than a blanket approach based on an overly generalised "universal NAD decline" narrative. Combined with emerging data suggesting no global decline of NAD in human blood (see below), this atlas refines the role of NAD+ interventions in an evidence-graded longevity stack.

**Actionable Takeaway:** If you're considering NAD+ precursors, this research suggests focusing on interventions that are known to impact specific tissues or conditions where NAD modulation is most effective. Combine supplementation with lifestyle factors known to support NAD, such as regular exercise and circadian alignment, rather than relying solely on high-dose supplementation.

Tyrosine Levels: A Negative Biomarker of Lifespan

**What was found:** A large observational study investigating blood amino acid profiles and lifespan identified tyrosine as a significant outlier. Men with higher circulating tyrosine levels exhibited shorter lifespans, with modelling suggesting they could lose close to one year of life expectancy compared to those with lower levels [6].

**Why it matters:** This highlights the growing importance of amino acid patterning as a longevity biomarker, complementing traditional metrics like lipids and glucose. Elevated tyrosine, involved in catecholamine and thyroid hormone synthesis, may signal over-nutrition, altered protein turnover, or metabolic stress. This finding suggests a future where amino-acid panel-based risk scoring could tailor dietary protein sources and amounts in longevity protocols, moving beyond just total protein grams. It’s another nuanced layer to the `/protocols/healthspan-foundation` we often discuss.

**Actionable Takeaway:** While more research is needed to establish causality and specific dietary recommendations, it might be prudent to moderate excessive intake of tyrosine-rich foods, particularly if you consume a very high-protein diet without varied sources. Consider a more balanced, plant-dominant diet with judicious intake of animal proteins. Regular blood tests that include amino acid panels could become a useful tool for personalised longevity insights.

Modified Mediterranean Diet: Low-Protein, Methionine-Tuned for Healthspan

**What was found:** Researchers at the University of Southern California tested a modified Mediterranean-style diet in ageing mice. This diet, predominantly plant and fish-based with low protein and carefully balanced methionine (an amino acid abundant in meat, eggs, and dairy), led to increased healthspan, reduced body fat, and lower frailty indices compared to control groups [12].

**Why it matters:** This study provides compelling mechanistic and phenotypic support for methionine restriction and moderate protein intake as potent longevity levers, but crucially, within a dietary framework that closely resembles human Mediterranean eating patterns. It underscores that protein quality and methionine content might be as vital as total calories for mitigating age-related frailty, bridging geroscience with practical nutrition. This nudges human protocol design towards plant-dominant, fish-inclusive diets with moderated animal protein and methionine loads, especially after midlife, to balance sarcopenia risk against metabolic and frailty ageing. This is a powerful addition to the discussions around optimal `/supplements` for diet support.

**Actionable Takeaway:** Adopt a diet that leans heavily on plant-based foods, includes fish, and moderates red meat and dairy. Focus on diverse protein sources to ensure amino acid balance without excessive methionine. This doesn't mean strict vegetarianism, but rather a strategic shift in dietary emphasis to support long-term health and reduced frailty.

Multi-Organ Ageing Map: Protein Blood Panel to Predict Future Disease

**What was found:** Stanford researchers analysed over 7,000 blood proteins in more than 60,000 individuals to estimate the biological age of over 40 distinct cell types. These 'cell-age' estimates were remarkably predictive, flagging risks for Alzheimer’s disease, ALS, and lung cancer years before clinical diagnosis [4]. While currently a research tool, this represents a significant leap in multi-proteomic ageing clocks.

**Why it matters:** This is a major advancement in AI-driven, multi-proteomic ageing diagnostics. The sheer scale of data (60,000 participants, 7,000 proteins) provides an unprecedented training dataset for developing clinical-grade ageing diagnostics, risk stratification, and N-of-1 tracking of intervention responses. For those of us using `/wearables` and personal data, this points to a future where sophisticated blood-based 'cell age' panels could offer a more sensitive and disease-predictive alternative to existing single DNAm clocks or basic lipid/glucose profiling.

**Actionable Takeaway:** This technology isn't yet commercially available, but it highlights the future of personalised health. Engage with regular comprehensive health checks and advocate for increasingly sophisticated biomarker analysis. Staying abreast of developments in multi-omic blood tests will be crucial for early risk identification.

Semaglutide: Slowing Biological Ageing via DNA-Methylation Clocks

**What was found:** A re-analysis of a 32-week semaglutide trial involving 84 adults revealed that several DNA-based biological ageing clocks showed slowed progression of biological age in the semaglutide group compared to controls. Although this ageing analysis was exploratory and not the trial's primary endpoint, the signal is notable [4].

**Why it matters:** This pushes GLP-1 agonists beyond their established roles in weight loss and cardiometabolic health, positioning them as potential pharmacological geroprotectors with direct impacts on epigenetic ageing trajectories. It supports the hypothesis that aggressive metabolic risk reduction, achieved within months, can translate into measurable changes in ageing clocks. For clinicians, this suggests that decisions regarding GLP-1s in high-risk midlife patients might one day be informed not only by diabetes/CVD risk but also by their biological age trajectories, once larger trials confirm these signals. Our previous pieces on GLP-1s, like "GLP-1 drugs beyond weight loss: the longevity signal nobody expected", are becoming even more relevant.

**Actionable Takeaway:** If you have metabolic dysfunction (e.g., pre-diabetes, obesity) and are discussing treatment options with your doctor, inquire about GLP-1 agonists like semaglutide. Beyond their primary indications, these drugs are showing promising signs in slowing aspects of biological ageing. This is a prescription medication and should only be used under medical supervision [/legal/disclaimer].

Psilocybin Neuroplasticity Trial in Older Adults (60-85)

**What was found:** The Berkeley Center for the Science of Psychedelics is recruiting healthy adults aged 60-85 for a trial to investigate psilocybin's impact on neuroplasticity and successful ageing. Participants will receive a 1-30mg dose of psilocybin and undergo three MRI scans to quantify changes in brain structure and function [18].

**Why it matters:** This marks a structured effort to evaluate psychedelics as neuroplasticity-enhancing interventions specifically for older adults, moving beyond their common application in mood disorders. If psilocybin can induce durable changes in brain connectivity, synaptic density, or neurovascular coupling, it could become a component of future cognitive-longevity protocols, potentially synergising with cognitive training and lifestyle optimisation. This is a fascinating intersection of `/research` and `/protocols/cognitive-enhancement`.

**Actionable Takeaway:** This research is very much in its early stages, and psilocybin remains a controlled substance in the UK. However, staying informed about clinical trials exploring neuroplasticity and cognitive function in ageing populations is valuable. Focus on proven methods for cognitive health, such as continuous learning, complex problem-solving, and managing stress, while keeping an eye on this emerging area.

Emerging Consensus: NAD Levels May Not Globally Decline with Age in Human Blood

**What was found:** Recent expert reviews and papers suggest that NAD levels in human blood do not consistently show a global decline with age. While some tissues exhibit NAD changes and supplementation with NR (nicotinamide riboside) can raise NAD in certain compartments, claims of a universal age-related NAD decline may be overstated [15].

**Why it matters:** This directly impacts the evidence-graded guidance for NAD+ precursors like NR and NMN. It implies that their benefits might be more tissue-specific and incremental rather than broad "anti-ageing" effects. This reinforces the importance of using multi-organ ageing maps (as discussed earlier) to strategically focus NAD interventions where the biology truly warrants it. From a protocol perspective, it suggests prioritising higher-effect levers—like metabolic control, resistance training, and sleep architecture—over heavy reliance on NAD precursors alone. Our `/supplements/nmn` content covers the nuances of these compounds.

**Actionable Takeaway:** If you're using NAD+ precursors, consider them part of a broader strategy rather than a standalone solution. Focus on foundational longevity practices—exercise, diet, sleep, and stress management—which are known to influence NAD metabolism indirectly and effectively. The evidence suggests these fundamentals might be more impactful than blanket high-dose NAD+ supplementation, especially if your blood NAD levels are already within a healthy range.

Gaps we are watching

While this week has brought a wealth of fascinating insights, there are always areas where the evidence remains thin or where our understanding is still nascent. Firstly, the long-term human efficacy and safety of novel small-molecule geroprotectors like TM5614 and piceatannol, particularly when used chronically, requires much more robust investigation beyond initial trials. We also need to see if the biological age reversal seen translates into tangible healthspan improvements and reduced incidence of age-related diseases. Secondly, the integration of AI-driven multi-omic diagnostics, like the advanced proteomic blood panels, into routine clinical practice in the UK is still several years away. The regulatory hurdles, cost implications, and validation against diverse populations will be significant, but we believe this area holds immense promise for personalised longevity interventions. Lastly, the ethical and practical implications of psychedelic interventions like psilocybin for neuroplasticity in older adults, especially outside of highly controlled clinical settings, presents a complex area we'll be watching closely.

Bottom line

This week's research underscores a crucial theme: the most potent longevity interventions are often synergistic and multi-faceted. We're seeing powerful signals from combined lifestyle approaches (fasting + exercise), precise dosing of established levers (resistance training), and the emergence of targeted small molecules that address fundamental ageing mechanisms. While the promise of compounds like TM5614 and piceatannol is exciting, the consistent message from the data remains that fundamental practices – thoughtful diet, regular and varied exercise, and metabolic control – form the bedrock of any effective healthspan strategy. Don't chase every new supplement; prioritise proven, high-impact behaviours that move the needle on validated biological ageing markers. For a comprehensive approach, our `/protocols/healthspan-foundation` details these core strategies.